

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 8)*

Zivo Bioscience, Inc.

(Name of Issuer)

Common Stock, par value \$.001 per share

(Title of Class of Securities)

98978N101

(CUSIP Number)

Strome Group, Inc.
Attn: Mark E. Strome 13535 Ventura Boule, Suite C-525
Sherman Oaks, CA, 91423
3108509700

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

12/26/2024

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 98978N101

1	Name of reporting person Mark E. Strome
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions) OO

5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6	Citizenship or place of organization UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 220,349.00
	8 Shared Voting Power 222,505.00
	9 Sole Dispositive Power 220,349.00
	10 Shared Dispositive Power 222,505.00
11	Aggregate amount beneficially owned by each reporting person 442,854.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>
13	Percent of class represented by amount in Row (11) 12.20 %
14	Type of Reporting Person (See Instructions) IN, HC

SCHEDULE 13D

CUSIP No.	98978N101
-----------	-----------

1	Name of reporting person Strome Group, Inc.
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions) OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6	Citizenship or place of organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 222,505.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 222,505.00
11	Aggregate amount beneficially owned by each reporting person 222,505.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>	
13	Percent of class represented by amount in Row (11) 6.13 %	
14	Type of Reporting Person (See Instructions) CO	

SCHEDULE 13D

CUSIP No.	98978N101
-----------	-----------

1	Name of reporting person Strome Investment Management, LP	
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)	
3	SEC use only	
4	Source of funds (See Instructions) OO	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 222,505.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 222,505.00

11	Aggregate amount beneficially owned by each reporting person 222,505.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>
13	Percent of class represented by amount in Row (11) 6.13 %
14	Type of Reporting Person (See Instructions) IA, PN

SCHEDULE 13D

CUSIP No.	98978N101
-----------	-----------

1	Name of reporting person Strome Mezzanine Fund, LP
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)
3	SEC use only
4	Source of funds (See Instructions) OO
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>
6	Citizenship or place of organization DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00
	8 Shared Voting Power 45,064.00
	9 Sole Dispositive Power 0.00
	10 Shared Dispositive Power 45,064.00
11	Aggregate amount beneficially owned by each reporting person 45,064.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>
13	Percent of class represented by amount in Row (11) 1.24 %
14	Type of Reporting Person (See Instructions) PN

SCHEDULE 13D

CUSIP No.	98978N101
-----------	-----------

1	Name of reporting person Strome Mezzanine Fund II, LP	
2	Check the appropriate box if a member of a Group (See Instructions) <input type="checkbox"/> (a) <input type="checkbox"/> (b)	
3	SEC use only	
4	Source of funds (See Instructions) WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) <input type="checkbox"/>	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 0.00
	8	Shared Voting Power 165,000.00
	9	Sole Dispositive Power 0.00
	10	Shared Dispositive Power 165,000.00
11	Aggregate amount beneficially owned by each reporting person 165,000.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) <input type="checkbox"/>	
13	Percent of class represented by amount in Row (11) 4.55 %	
14	Type of Reporting Person (See Instructions) PN	

SCHEDULE 13D

Item 1. Security and Issuer

- (a) Title of Class of Securities:
Common Stock, par value \$.001 per share
- (b) Name of Issuer:
Zivo Bioscience, Inc.

(c) **Address of Issuer's Principal Executive Offices:**

21 E. Long Lake Road, Suite 100, Bloomfield Hills, MICHIGAN , 48304.

Item 1 Comment:

This statement on Schedule 13D/A (the "Amendment") relates to the common stock, \$0.001 par value (the "Common Stock"), of Zivo Bioscience, Inc., a Michigan corporation (the "Issuer"). The Issuer's principal offices are located at 21 E. Long Lake Road, Suite 100, Bloomfield Hills, Michigan 48304.

Item 2. Identity and Background

- (a) Mark E. Strome; Strome Group, Inc.; Strome Investment Management, LP (the "Manager"); Strome Mezzanine Fund, LP and Strome Mezzanine Fund II, LP (the "Fund," and together with the Strome Mezzanine Fund, LP, the "Funds").
- (b) The principal business address for Mr. Strome, Strome Group, Inc. and the Manager is 13535 Ventura Blvd., Ste C-525, Sherman Oaks, CA 91423, and the principal business address for the Funds is 1688 Meridian Ave., Suite 727, Miami Beach, Florida 33139.
- (c) The principal occupation of Mr. Strome is serving as the President of the Strome Group, Inc. The principal business of Strome Group, Inc. is to act as a holding company for business investments. The principal business of the Manager is to serve as a general partner and investment manager of the Funds. The principal business of each of the Funds is to make investments.
- (d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
- (e) During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
- (f) Mark E. Strome is a United States citizen; Strome Group, Inc. is a Delaware corporation; and the Manager and the Funds are each a Delaware limited partnership.

Item 3. Source and Amount of Funds or Other Consideration

On December 26, 2024, pursuant to the Issuer's private offering of Common Stock, the Fund purchased, from its working capital, 75,000 shares of Common Stock from the Issuer at \$20.19 per share and in connection with such purchase, the Issuer issued to the Fund, for no additional consideration, Common Stock purchase warrants ("Warrants") exercisable for 7,500 shares of Common Stock. Prior to the date of this Amendment, the Fund also acquired shares of Common Stock and Warrants from the Issuer as follows: (i) in July 2024, 20,000 shares of Common Stock at \$7.84 per share and Warrants exercisable for 2,000 shares of Common Stock for no additional consideration; (ii) in July 2024, 25,000 shares of Common Stock at \$8.05 per share and Warrants exercisable for 2,500 shares of Common Stock for no additional consideration; and (iii) in August 2024, 30,000 shares of Common Stock at \$8.444 per share and Warrants exercisable for 3,000 shares of Common Stock for no additional consideration. As a result, the Fund holds 150,000 shares of Common Stock and Warrants exercisable for 15,000 shares of Common Stock as of the date of this Amendment.

Item 4. Purpose of Transaction

The Reporting Persons acquired the securities covered by this Amendment for investment purposes, in the ordinary course of business, and has no present plans or proposals with respect to any of the matters set forth in subparagraphs (a)-(j) of Item 4 of Schedule 13D.

The Reporting Persons intend to assess their investment in the Issuer on a continuing basis. Depending on various factors, including without limitation their perception of the Issuer's actual and prospective financial condition, results of operations, cash flows, liquidity, capital resources and other attributes, the respective price levels of the Common Stock, conditions in the securities markets, and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they may deem appropriate, including without limitation purchasing additional shares of Common Stock or other securities of the Issuer or selling or otherwise disposing some or all of their shares of Common Stock or other securities of the Issuer.

Item 5. Interest in Securities of the Issuer

- (a) The aggregate number and percentage of the shares of Common Stock outstanding beneficially owned by each Reporting Person set forth below and on pages 2-5 hereof are based on 3,546,335 shares of Common Stock outstanding as of November 8, 2024.
- (b) Mark E. Strome: (1) Sole Voting Power: 220,349 (2) Shared Voting Power: 222,505 (3) Sole Dispositive Power: 220,349 (4) Shared Dispositive Power: 222,505 Strome Group, Inc.: (1) Sole Voting Power: 0 (2) Shared Voting Power: 222,505 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 222,505 Strome Investment Management, LP: (1) Sole Voting Power: 0 (2) Shared Voting Power: 222,505 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 222,505 Strome Mezzanine Fund, LP: (1) Sole Voting Power: 0 (2) Shared Voting Power: 45,064 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 45,064 Strome Mezzanine Fund II, LP: (1) Sole Voting Power: 0 (2) Shared Voting Power: 165,000 (3) Sole Dispositive Power: 0 (4) Shared Dispositive Power: 165,000
- (c) Except as disclosed in this Amendment, none of the Reporting Persons has effected any transactions in shares of Common Stock during the past sixty days.
- (d) Not applicable.
- (e) Not applicable.

Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Except as provided herein, no Reporting Person is a party to any contract, arrangement, understanding or relationship with respect to any securities of the Issuer.

Item 7. Material to be Filed as Exhibits.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mark E. Strome

Signature: /s/ Mark E. Strome
Name/Title: Mark E. Strome
Date: 12/31/2024

Strome Group, Inc.

Signature: /s/ Mark E. Strome
Name/Title: Mark E. Strome/President
Date: 12/31/2024

Strome Investment Management, LP

Signature: Strome Group, Inc.
Name/Title: General Partner
Date: 12/31/2024

Signature: /s/ Mark E. Strome
Name/Title: Mark E. Strome/President
Date: 12/31/2024

Strome Mezzanine Fund, LP

Signature: Strome Investment Management, LP
Name/Title: General Partner
Date: 12/31/2024

Signature: Strome Group, Inc.
Name/Title: General Partner
Date: 12/31/2024

Signature: /s/ Mark E. Strome
Name/Title: Mark E. Strome/President
Date: 12/31/2024

Strome Mezzanine Fund II, LP

Signature: Strome Investment Management, LP
Name/Title: General Partner
Date: 12/31/2024

Signature: Strome Group, Inc.
Name/Title: General Partner
Date: 12/31/2024

Signature: /s/ Mark E. Strome
Name/Title: Mark E. Strome/President
Date: 12/31/2024

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, Strome Investment Management, LP, Strome Group, Inc. and Mark E. Strome agree separately with Strome Mezzanine Fund, LP and Strome Mezzanine Fund II, LP to the joint filing on behalf of each of them a statement on Schedule 13D/A (including amendments thereto, if any) with respect to the shares of common stock of Zivo Bioscience, Inc., a Michigan corporation, and that this Agreement may be included as an Exhibit to such joint filing.

Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the undersigned hereby execute this Agreement as of December 31, 2024.

/s/ Mark E. Strome

Mark E. Strome

Strome Group, Inc.

By: /s/ Mark E. Strome

Name: Mark E. Strome

Its: President

Strome Investment Management, LP

By: Strome Group, Inc.

Its: General Partner

By: /s/ Mark E. Strome

Name: Mark E. Strome

Its: President

Strome Mezzanine Fund, LP

By: Strome Investment Management, LP

Its: General Partner

By: Strome Group, Inc.

Its: General Partner

By: /s/ Mark E. Strome

Name: Mark E. Strome

Its: President

Strome Mezzanine Fund II, LP

By: Strome Investment Management, LP

Its: General Partner

By: Strome Group, Inc.

Its: General Partner

By: /s/ Mark E. Strome

Name: Mark E. Strome

Its: President